Biopharmaceuticals from microorganisms: from production to purification

Brazilian Journal of Microbiology

Volumn 47, Issue , 2016, Pages 51-63

  Jozala, Angela Faustino ^a   Geraldes, Danilo Costa ^b   Tundisi, Louise Lacalendola ^b   Feitosa, Valker de Araújo ^c   Breyer, Carlos Alexandre ^d   Cardoso, Samuel Leite ^e   Mazzola, Priscila Gava ^b   de Oliveira Nascimento, Laura ^b   Rangel Yagui, Carlota de Oliveira ^c   Magalhães, Pérola de Oliveira ^e   de Oliveira, Marcos Antonio ^d   Pessoa, Adalberto ^c  

^a UNIVERSITY OF SOROCABA   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^e UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Biopharmaceuticals; Biotechnology; Downstream process; Fermentation process; Upstream process

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; DRUG; RECOMBINANT PROTEIN;

BIOTECHNOLOGY; DRUG INDUSTRY; FERMENTATION; HUMAN; MICROBIOLOGICAL EXAMINATION;

BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; BIOTECHNOLOGY; DRUG INDUSTRY; FERMENTATION; HUMANS; MICROBIOLOGICAL TECHNIQUES; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS;

EID: 85003794105     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1016/j.bjm.2016.10.007     Document Type: Review

References (82)

1. 1 Valderrama-Rincon, J.D., Fisher, A.C., Merritt, J.H., et al. An engineered eukaryotic protein glycosylation pathway in Escherichia coli. Nat Chem Biol 8:5 (2012), 434–436.
2. 2 Rodríguez, V., Asenjo, J.A., Andrews, B.A., Design and implementation of a high yield production system for recombinant expression of peptides. Microb Cell Fact 13 (2014), 1–10.
3. 3 Sekhon, B.S., Biopharmaceuticals: an overview. Thai J Pharm Sci 34 (2010), 1–19.
4. 4 Tufts Center for the Study of Drug Development. Tufts CSDD assessment of cost to develop and win marketing approval for a new drug now published. Available from: http://csdd.tufts.edu/news/complete_story/tufts_csdd_rd_cost_study_now_published [Accessed 12.07.16].
5. 5 Crommelin, D.J., Storm, G., Verrijk, R., De Leede, L., Jiskoot, W., Hennink, W.E., Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 266:1–2 (2003), 3–16.
6. 6 Cox, D.B.T., Platt, R.J., Zhang, F., Therapeutic genome editing: prospects and challenges. Nat Med 21:2 (2015), 121–131.
7. 7 Chen, H.L., Chang, J.K., Tang, R.B., Current recommendations for the Japanese encephalitis vaccine. J Chin Med Assoc 78:5 (2015), 271–275.
8. 8 Deng, Y., Wang, C.C., Choy, K.W., et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538:2 (2014), 217–227.
9. 9 Wittrup, A., Lieberman, J., Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 16:9 (2015), 543–552.
10. 10 Leader, B., Baca, Q.J., Golan, D.E., Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7:1 (2008), 21–39.
11. 11 Zawaira, A., Pooran, A., Barichievy, S., Chopera, D., A discussion of molecular biology methods for protein engineering. Mol Biotechnol 51:1 (2012), 67–102.
12. 12 Beck, A., Biosimilar, Biobetter and next generation therapeutic antibodies. MAbs 3:2 (2011), 107–110.
13. 13 Strohl, W.R., Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29:4 (2015), 215–239.
14. 14 Sandeep, V., Parveen, J., Chauhan, P., Biobetters: the better biologics and their regulatory overview. Int J Drug Regul Aff 4:1 (2016), 13–20.
15. 15 Mitragotri, S., Burke, P.A., Langer, R., Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 13:9 (2014), 655–672.
16. 16 BIOPHARMA: Biopharmaceutical Products in the U.S. and European Markets. This is a list of new full FDA approvals for biopharmaceutical products (unless otherwise noted). Available from: http://www.biopharma.com/approvals.html [Accessed 12.07.16].
17. 17 Mullard, A., EMA greenlights second gene therapy. Nat Rev Drug Discov, 15(5), 2016, 299.
18. 18 Carr, D.R., Bradshaw, S.E., Gene therapies: the challenge of super-high-cost treatments and how to pay for them. Regen Med 11:4 (2016), 381–393.
19. 19 Carter, P.J., Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317:9 (2011), 1261–1269.
20. 20 Courtois, F., Schneider, C.P., Agrawal, N.J., Trout, B.L., Rational design of biobetters with enhanced stability. J Pharm Sci 104:8 (2015), 2433–2440.
21. 21 Chirino, A.J., Ary, M.L., Marshall, S., Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9:2 (2004), 82–90.
22. 22 Whitford, D., The three-dimensional structure of protein. Proteins: Structure and Function, 1st ed., 2005, John Wiley & Sons, West Sussex, England, 39–83.
23. 23 Courtois, F., Agrawal, N.J., Lauer, T.M., Trout, B.L., Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. MAbs 8:1 (2016), 99–112.
24. 24 Huang, M., Shao, Y., Hou, J., et al. Structural asymmetry of phosphodiesterase-9a and a unique pocket for selective binding of a potent enantiomeric inhibitor. Mol Pharmacol 88:5 (2015), 836–845.
25. 25 Aprile, F.A., Sormanni, P., Vendruscolo, M., A rational design strategy for the selective activity enhancement of a molecular chaperone toward a target substrate. Biochemistry 54:32 (2015), 5103–5112.
26. 26 Carter, P., Site-directed mutagenesis. Biochem J 237 (1986), 1–7.
27. 27 Hsieh, P., Vaisvila, R., Protein engineering: single or multiple site-directed mutagenesis. Methods Mol Biol 978 (2013), 173–186.
28. 28 Kowalsky, C.A., Faber, M.S., Nath, A., et al. Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing. J Biol Chem 290:44 (2015), 26457–26470.
29. 29 Gronemeyer, P., Ditz, R., Strube, J., Trends in upstream and downstream process development for antibody manufacturing. Bioengineering 1:4 (2014), 188–212.
30. 30 Schmidell, W., Lima, U. de A., Aquarone, E., Borzani, W., Biotecnologia Industrial. v.2.1a ed. Engenharia Bioquímica, 2001, Blucher, São Paulo, Brasil.
31. 31 Park, W.H., Atkinson, J.P., The relation of the toxicity of diphtheria toxin to its neutralizing value upon antitoxin at different stages in the growth of culture. J Exp Med 3:4–5 (1898), 513–532.
32. 32 Baxter, A.G., The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7:11 (2007), 904–912.
33. 33 Igea, J.M., The history of the idea of allergy. Allergy 68:8 (2013), 966–973.
34. 34 Graf, C.J., Woodworth, J.R., Seger, M.E., Holcombe, J.H., Bowsher, R.R., Lynch, R., Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers. J Pharm Sci 88:10 (1999), 991–995.
35. 35 Lopes, A.M., Oliveira-Nascimento, L., Ribeiro, A., et al. Therapeutic L-asparaginase: upstream, downstream and beyond. Crit Rev Biotechnol 23 (2015), 1–18 [Epub ahead of print].
36. 36 Syed, Y.Y., McCormack, P.L., Exenatide extended-release: an updated review of its use in type 2 diabetes mellitus. Drugs 75:10 (2015), 1141–1152.
37. 37 Powell-Jackson, J., Weller, R.O., Kennedy, P., Preece, M.A., Whitcombe, E.M., Newsom-Davis, J., Creutzfeldt-Jakob disease after administration of human growth hormone. Lancet (London, England) 2:8449 (1985), 244–246.
38. 38 Demain, A.L., Vaishnav, P., Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 27:3 (2009), 297–306.
39. 39 Rosenfeld, L., Insulin: discovery and controversy. Clin Chem 48:12 (2002), 2270–2288.
40. 40 Lim, J.C., Choi, H.-I., Park, Y.S., et al. Irreversible oxidation of the active-site cysteine of peroxiredoxin to cysteine sulfonic acid for enhanced molecular chaperone activity. J Biol Chem 283:43 (2008), 28873–28880.
41. 41 Zhao, K., Ping, W., Li, Q., et al. Aspergillus niger var. taxi, a new species variant of taxol-producing fungus isolated from Taxus cuspidata in China. J Appl Microbiol 107:4 (2009), 1202–1207.
42. 42 O'Connell, S., Walsh, G., Application relevant studies of fungal beta-galactosidases with potential application in the alleviation of lactose intolerance. Appl Biochem Biotechnol 149:2 (2008), 129–138.
43. 43 Oliveira, C., Guimarães, P.M.R., Domingues, L., Recombinant microbial systems for improved β-galactosidase production and biotechnological applications. Biotechnol Adv 29:6 (2011), 600–609.
44. 44 Ruiz-Matute, A.I., Corzo-Martínez, M., Montilla, A., Olano, A., Copovi, P., Corzo, N., Presence of mono-, di- and galactooligosaccharides in commercial lactose-free UHT dairy products. J Food Compos Anal 28:2 (2012), 164–169.
45. 45 Zabian Bassetto, R., Rodrigues, M.C.C., Almeida, M.M., de Chiquetto, N.C., Caracterização da produção de galactooligossacarideos por fermentação sequencial. Evidência Ciência e Biotecnogia 14 (2014), 57–68.
46. 46 Li, C.-W., Song, R.-Q., Yang, L.-B., Deng, X., Isolation, purification, and structural identification of an antifungal compound from a trichoderma strain. J Microbiol Biotechnol 25:8 (2015), 1257–1264.
47. 47 Svahn, K.S., Chryssanthou, E., Olsen, B., Bohlin, L., Göransson, U., Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B. Fungal Biol Biotechnol 2:1 (2015), 2–8.
48. 48 Watanabe, K., Collagenolytic proteases from bacteria. Appl Microbiol Biotechnol 63:5 (2004), 520–526.
49. 49 Kumar, C.G., Takagi, H., Microbial alkaline proteases: from a bioindustrial viewpoint. Biotechnol Adv 17:7 (1999), 561–594.
50. 50 Carrez, D., Janssens, W., Degrave, P., et al. Heterologous gene expression by filamentous fungi: secretion of human interleukin-6 by Aspergillus nidulans. Gene 94:2 (1990), 147–154.
51. 51 Yadwad, V.B., Wilson, S., Ward, O.P., Effect of culture conditions and induction strategies on production of human interleukin-6 by a recombinant Aspergillus nidulans strain. Mycol Res 100:3 (1996), 356–360.
52. 52 Maras, M., van Die, I., Contreras, R., van den Hondel, C.A., Filamentous fungi as production organisms for glycoproteins of bio-medical interest. Glycoconj J 16:2 (1999), 99–107.
53. 53 Azevedo, A.M., Rosa, P.A.J., Ferreira, I.F., Aires-Barros, M.R., Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. Trends Biotechnol 27:4 (2009), 240–247.
54. 54 Rathore, A.S., Kapoor, G., Application of process analytical technology for downstream purification of biotherapeutics. J Chem Technol Biotechnol 90:2 (2015), 228–236.
55. 55 Rosa, P.A.J., Ferreira, I.F., Azevedo, A.M., Aires-Barros, M.R., Aqueous two-phase systems: a viable platform in the manufacturing of biopharmaceuticals. J Chromatogr A 1217:16 (2010), 2296–2305.
56. 56 Fields, C., Li, P., O'Mahony, J.J., Lee, G.U., Advances in affinity ligand-functionalized nanomaterials for biomagnetic separation. Biotechnol Bioeng 113:1 (2016), 11–25.
57. 57 Weinacker, D., Rabert, C., Zepeda, A.B., Figueroa, C.A., Pessoa, A., Farías, J.G., Applications of recombinant Pichia pastoris in the healthcare industry. Braz J Microbiol 44:4 (2013), 1043–1048.
58. 58 Roque, A.C.A., Lowe, C.R., Taipa, M.A., Antibodies and genetically engineered related molecules: production and purification. Biotechnol Prog 20:3 (2004), 639–654.
59. 59 Faria, R.P.V., Rodrigues, A.E., Instrumental aspects of simulated moving bed chromatography. J Chromatogr A 1421 (2015), 82–102.
60. 60 Saraswat, M., Musante, L., Ravidá, A., Shortt, B., Byrne, B., Holthofer, H., Preparative purification of recombinant proteins: current status and future trends. Biomed Res Int 2013 (2013), 1–18.
61. 61 Lowe, C.R., Combinatorial approaches to affinity chromatography. Curr Opin Chem Biol 5:3 (2001), 248–256.
62. 62 Lowe, C.R., Lowe, A.R., Gupta, G., New developments in affinity chromatography with potential application in the production of biopharmaceuticals. J Biochem Biophys Methods 49:1–3 (2001), 561–574.
63. 63 Warikoo, V., Godawat, R., Brower, K., et al. Integrated continuous production of recombinant therapeutic proteins. Biotechnol Bioeng 109:12 (2012), 3018–3029.
64. 64 Jungbauer, A., Continuous downstream processing of biopharmaceuticals. Trends Biotechnol 31:8 (2013), 479–492.
65. 65 Freydell, E.J., Bulsink, Y., van Hateren, S., van der Wielen, L., Eppink, M., Ottens, M., Size-exclusion simulated moving bed chromatographic protein refolding. Chem Eng Sci 65:16 (2010), 4701–4713.
66. 66 Cramer, S.M., Holstein, M.A., Downstream bioprocessing: recent advances and future promise. Curr Opin Chem Eng 1:1 (2011), 27–37.
67. 67 Rosti, I.A., Ramanan, R.N., Tan, J.S., Ling, T.C., Ariff, A.B., Recovery of microquantities of human epidermal growth factor from Escherichia coli Homogenate and Pichia pastoris culture medium using expanded bed adsorption. Sep Sci Technol 49:5 (2014), 702–708.
68. 68 Xu, X., Hirpara, J., Epting, K., et al. Clarification and capture of high-concentration refold pools for E. coli-based therapeutics using expanded bed adsorption chromatography. Biotechnol Prog 30:1 (2014), 113–123.
69. 69 Rajamanickam, V., Herwig, C., Spadiut, O., Monoliths in bioprocess technology. Chromatography 2:2 (2015), 195–212.
70. 70 Ribeiro, D.A., Passos, D.F., Ferraz, H.C., Castilho, L.R., Anion-exchange purification of recombinant factor IX from cell culture supernatant using different chromatography supports. J Chromatogr B Anal Technol Biomed Life Sci 938 (2013), 111–118.
71. 71 Krainer, F.W., Pletzenauer, R., Rossetti, L., Herwig, C., Glieder, A., Spadiut, O., Purification and basic biochemical characterization of 19 recombinant plant peroxidase isoenzymes produced in Pichia pastoris. Protein Expr Purif 95 (2014), 104–112.
72. 72 Li, F., Lee, B., Zho, J.X., Tressel, T., Yang, X., Current therapeutic antibody production and process optimization. BioProccessing J 5 (2006), 16–25.
73. 73 Gottschalk, U., The future of downstream processing. BioPharm Int 24:9 (2011), 38–47.
74. 74 Yu, L.X., Amidon, G., Khan, M.A., et al. Understanding pharmaceutical quality by design. AAPS J 16:4 (2014), 771–783.
75. 75 Glassey, J., Gernaey, K.V., Clemens, C., et al. Process analytical technology (PAT) for biopharmaceuticals. Biotechnol J 6:4 (2011), 369–377.
76. 76 bioTRAK database. Available from: http://bptc.com [Accessed 14.07.16].
77. 77 Gal R. Biosimilars: Reviewing US law and US/EU patents; bottom up model suggests 12 products and $7-$8B market by 2020. Bernstein Research. Available from: http://www.gabionline.net/layout/set/print/content/view/full/2030 [Accessed 06.10.16].
78. 78 Dezzani L. Top 25 Pharmaceutical Products in 2015. Available from: https://igeahub.com/2016/04/30/top-25-pharmaceutical-products-in-2015/ [Accessed 11.10.16].
79. 79 Polimeni, G., Trifirò, G., Ingrasciotta, Y., Caputi, A.P., The advent of biosimilars for the treatment of diabetes: current status and future directions. Acta Diabetol 52:3 (2015), 423–431.
80. 80 Kresse, G.-B., Biosimilars – science, status, and strategic perspective. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft für Pharm Verfahrenstechnik eV 72:3 (2009), 479–486.
81. 81 Hua, S., Oh, M.J., Ozcan, S., Seo, Y.S., Grimm, R., An, H.J., Technologies for glycomic characterization of biopharmaceutical erythropoietins. TrAC Trends Anal Chem 68 (2015), 18–27.
82. 82 Dörner, T., Kay, J., Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 11:12 (2015), 713–724.